Oncology – Page 12

Adipocyte-Driven Immunometabolic Suppression in Pancreatic Cancer: The 12,13-DiHOME/PPARγ/TAN Axis

By MedXY 06/03/2026

This review explores how tumour-infiltrating adipocytes release 12,13-DiHOME to trigger neutrophil ferroptosis and CXCL2 production, ultimately subverting CD8+ T cell-mediated immunity in pancreatic ductal adenocarcinoma.

Gastroenterology news Oncology

Quorum-Sensing Molecules Elevated in Long-Standing Ulcerative Colitis May Help Drive Colitis-Associated Cancer

By MedXY 06/03/2026

Bacterial quorum-sensing molecules, especially C6-scAHL, were elevated in long-standing ulcerative colitis and promoted colon tumor growth in mice, suggesting a new microbiome-driven pathway for colitis-associated cancer.

Diabetes & Endocrinology news Oncology

Detectable Antithyroglobulin Antibodies Above the Assay LOQ Signal Higher Recurrence Risk in Papillary Thyroid Carcinoma Despite Undetectable Thyroglobulin

By MedXY 06/03/2026

In papillary thyroid carcinoma treated with thyroidectomy and RAI, TgAb levels above the assay’s limit of quantification identified patients with higher long-term recurrence risk despite undetectable serum thyroglobulin.

news OB/GYN & Women’s Health Oncology

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial

By MedXY 06/03/2026

Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in hormone receptor-positive, ERBB2-negative advanced breast cancer with manageable toxicity and preserved quality of life.

$Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma$

Hematology-Oncology news Oncology

Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma

By MedXY 06/02/2026

A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.

Hematology-Oncology news Oncology

Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS

By MedXY 06/02/2026

A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and encouraging early survival outcomes.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population

By MedXY 06/01/2026

A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.

Gastroenterology news Oncology

Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison

By MedXY 06/01/2026

A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.

news OB/GYN & Women’s Health Oncology

More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort

By MedXY 06/01/2026

A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority population.

news Oncology Psychiatry

Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer

By MedXY 05/31/2026

A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and thyroid tumors.

Hematology-Oncology news Oncology

Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL

By MedXY 05/29/2026

miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.

news Oncology Psychiatry

When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed

By MedXY 05/29/2026

A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.

news Oncology Psychiatry

Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan

By MedXY 05/29/2026

A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.

news Oncology Public Health

Embedding Tobacco Treatment Into Cancer Care Achieved Universal Screening but Exposed Persistent Gaps in Cessation Assistance

By MedXY 05/29/2026

A cancer program quality improvement initiative reached a 100% smoking-status ask rate through an electronic hard stop, but assistance for identified smokers remained inconsistent, underscoring the implementation gap between screening and effective tobacco treatment.

news OB/GYN & Women’s Health Oncology

Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma

By MedXY 05/29/2026

This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.

Gastroenterology news Oncology

Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer

By MedXY 05/28/2026

Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.

Hematology-Oncology news Oncology

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models

By MedXY 05/27/2026

MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.

news Oncology Otorhinolaryngology

Volumetric Thresholds After Glossectomy May Predict Feeding Tube Dependence and Poor Speech

By MedXY 05/27/2026

A retrospective cohort study suggests that preoperative tumor burden, extent of tongue resection, and degree of volume restoration are strongly associated with swallowing and speech outcomes after glossectomy.

General Surgery news Oncology

Most Patients With Uncertain Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Still Harbor Residual Disease

By MedXY 05/27/2026

In the SANO cohort, 85% of patients with uncertain post-chemoradiotherapy response had residual tumor at esophagectomy, supporting surgery for most, while highlighting a notable complete response subgroup among squamous cell carcinoma with non-traversable lesions.

news Oncology Pathology & Lab Medicine/Bệnh học

Molecular and Spatial Differences in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer With Short vs Long-Term Survival

By MedXY 05/26/2026

This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microenvironment may shape survival outcomes.